FDA Clears Riverian X-Ray Comparison Software

The Food and Drug Administration has granted pre-market notification clearance for a new software that digitally compares past and present chest x-rays. Riverian Technologies announced this week that the FDA had granted 501(k) clearance for its Temporal Comparison software that can help identify nodules that may be early stage lung cancer. The software aligns current and prior chest x-rays of the same patient in order to pinpoint subtle changes that might not be spotted otherwise. Compared to analyzing x-rays side by side, 15 radiologists demonstrated a 12.4% improvement “sensitivity for actionable solitary pulmonary nodules” using the comparison software in a study of 422 pairs of chest x-rays. “Lung tissue is very complex and it can be quite difficult to see changes, particularly in certain areas, such as the hilum and apices where vascular structures and bones come together,” said Steve Worrell, Chief Technology Officer at Riverain in a press release. The Food and Drug Administration has granted pre-market notification clearance for a new software that digitally compares past and present chest x-rays. Riverian Technologies announced this week that the FDA had granted 501(k) clearance for its Temporal Comparison software that can help identify nodules that may be early stage lung cancer. The software aligns current and prior chest x-rays of the same patient in order to pinpoint subtle changes that might not be spotted otherwise. Compared to analyzing x-rays side by side, 15 radiologists demonstrated a 12.4% improvement “sensitivity for actionable solitary pulmonary nodules” using the comparison software in a study of 422 pairs of chest x-rays. “Lung tissue is very complex and it can be quite difficult to see changes, particularly in certain areas, such as the hilum and apices where vascular structures and bones come together,” said Steve Worrell, Chief Technology Officer at Riverain in a press release.